Baystate Wealth Management LLC Buys 890 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jul 12th, 2023

Baystate Wealth Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 36,661 shares of the biopharmaceutical company’s stock after purchasing an additional 890 shares during the period. Baystate Wealth Management LLC’s holdings in Pfizer were worth $1,496,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Lam Group Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $25,000. Worth Asset Management LLC bought a new stake in Pfizer during the 1st quarter worth approximately $29,000. My Personal CFO LLC bought a new stake in Pfizer during the 4th quarter worth approximately $32,000. Mendota Financial Group LLC bought a new stake in Pfizer during the 4th quarter worth approximately $33,000. Finally, Freedom Wealth Alliance LLC bought a new stake in Pfizer during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 67.80% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $36.01 on Wednesday. The firm’s fifty day moving average price is $37.90 and its two-hundred day moving average price is $41.28. The stock has a market cap of $203.29 billion, a PE ratio of 7.09, a PEG ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $35.35 and a fifty-two week high of $54.93. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm had revenue of $18.28 billion for the quarter, compared to analysts’ expectations of $16.49 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The company’s revenue was down 28.8% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.55%. Pfizer’s dividend payout ratio is 32.28%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wells Fargo & Company decreased their price target on Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. Bank of America dropped their price objective on Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research note on Friday, April 21st. Morgan Stanley dropped their price target on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. Barclays decreased their price objective on Pfizer from $40.00 to $38.00 in a report on Tuesday. Finally, UBS Group decreased their price objective on Pfizer from $41.00 to $39.00 in a report on Friday, May 5th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $46.53.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Monday, May 8th. The shares were bought at an average price of $38.58 per share, with a total value of $38,580.00. Following the completion of the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.05% of the stock is currently owned by insiders.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.